Yusin J S, Klaustermeyer W, Simmons C W, Baum M
Greater Los Angeles VA Health Care System, Los Angeles, CA, USA.
Allergol Immunopathol (Madr). 2013 Sep-Oct;41(5):298-303. doi: 10.1016/j.aller.2012.06.003. Epub 2012 Nov 21.
Patients with a history of beta-lactam antibiotic allergy are often admitted to the hospital with severe or life-threatening infections requiring beta-lactam antibiotics. Strict avoidance of beta lactams to such patients may prevent them from getting adequate coverage and can lead to an increase in the use of alternative antibiotics, which can predispose to antibiotic resistance. Past studies revealed a lower incidence of pen allergy then patients' histories suggest. Fortunately today, there are three options for patients presenting with a history of beta-lactam allergy. Penicillin skin testing, beta-lactam challenge or beta-lactam desensitization. Recently Pre Pen has been FDA re-approved and when combined with Pen G is a valid way to determine if patients are able to tolerate beta-lactam antibiotic. When these agents are not available one must decide about desensitization or challenge. When a patient has a positive penicillin skin test, desensitization or beta-lactam avoidance are the only options. This paper reviews the safety of beta-lactam desensitization.
To perform a chart review on patients desensitised with beta lactam to determine if desensitizations can be performed safely without minimal complications.
A retrospective chart review was performed on allergy and immunology inpatient consultations for beta-lactam desensitization between September 2003 and August 2006 at the Cedars-Sinai Medical Centre in Los Angeles. Patient data and outcomes of desensitization were analysed.
A total of 13 intravenous desensitizations were performed on 12 patients. The patients consisted of eight females and four males with an average age of 65 years. Age range was 36-92 years old. All 13 intravenous desensitizations were completed without complications. No patient required a slower rate of desensitization or discontinuance of the desensitization. Patients were able to tolerate the initial therapeutic dose of their beta-lactam antibiotic and were then able to complete full therapeutic courses of their antibiotic.
Beta-lactam antibiotic sensitivity continues to present a challenging problem for physicians. Patients with drug resistant infections who are unable to obtain skin testing or who test positive to skin tests may need either a challenge or desensitization. Desensitization, saved for those with a convincing beta-lactam hypersensitivity history is often the choice of last resort given the associated cost and risk of anaphylaxis. However, once desensitization is complete, patients are usually able to tolerate full doses of antibiotics for full treatment length with minimal side effects.
有β-内酰胺类抗生素过敏史的患者常因严重或危及生命的感染而住院,这些感染需要使用β-内酰胺类抗生素。对这类患者严格避免使用β-内酰胺类药物可能会使他们得不到足够的抗感染治疗,并且可能导致替代抗生素使用增加,进而易引发抗生素耐药性。过去的研究显示,青霉素过敏的实际发生率低于患者自述的情况。幸运的是,如今对于有β-内酰胺类过敏史的患者有三种选择:青霉素皮肤试验、β-内酰胺激发试验或β-内酰胺脱敏治疗。最近,预青霉素(Pre Pen)已获美国食品药品监督管理局(FDA)重新批准,与青霉素G联合使用是确定患者是否能够耐受β-内酰胺类抗生素的有效方法。当无法获得这些药物时,必须决定进行脱敏治疗还是激发试验。当患者青霉素皮肤试验呈阳性时,脱敏治疗或避免使用β-内酰胺类药物是仅有的选择。本文综述了β-内酰胺类脱敏治疗的安全性。
对接受β-内酰胺类脱敏治疗的患者进行病历回顾,以确定脱敏治疗能否安全进行且并发症最少。
对2003年9月至2006年8月在洛杉矶雪松西奈医疗中心进行的关于β-内酰胺类脱敏治疗的过敏与免疫科住院会诊病例进行回顾性分析。分析患者数据及脱敏治疗结果。
共对12例患者进行了13次静脉脱敏治疗。患者包括8名女性和4名男性,平均年龄65岁,年龄范围为36 - 92岁。所有13次静脉脱敏治疗均顺利完成,无并发症发生。没有患者需要减慢脱敏速度或停止脱敏治疗。患者能够耐受β-内酰胺类抗生素的初始治疗剂量,随后能够完成抗生素的全程治疗。
β-内酰胺类抗生素敏感性问题对医生来说仍然具有挑战性。对于耐药感染患者,若无法进行皮肤试验或皮肤试验呈阳性,可能需要进行激发试验或脱敏治疗。鉴于脱敏治疗相关的费用和过敏风险,脱敏治疗通常是那些有确凿β-内酰胺类超敏反应病史患者的最后选择。然而,一旦脱敏治疗完成,患者通常能够耐受全剂量抗生素进行全程治疗,且副作用最小。